OncoVista Innovative Therapies (OncoVista Innovative Therapies) Change In Working Capital : $2.39 Mil (TTM As of Sep. 2015)

View and export this data going back to 2005. Start your Free Trial

What is OncoVista Innovative Therapies Change In Working Capital?

OncoVista Innovative Therapies's change in working capital for the quarter that ended in Sep. 2015 was $-0.47 Mil.

OncoVista Innovative Therapies's change in working capital for the fiscal year that ended in Dec. 2014 was $2.32 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

OncoVista Innovative Therapies Change In Working Capital Historical Data

The historical data trend for OncoVista Innovative Therapies's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoVista Innovative Therapies Change In Working Capital Chart

OncoVista Innovative Therapies Annual Data

Trend

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Change In Working Capital

Get a 7-Day Free Trial

-0.42

0.35

0.27

1.05

2.32

OncoVista Innovative Therapies Quarterly Data
	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15
Change In Working Capital	Get a 7-Day Free Trial															0.21	1.67	0.21	0.99	-0.47

OncoVista Innovative Therapies Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Sep. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.39 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

OncoVista Innovative Therapies Change In Working Capital Related Terms

Thank you for viewing the detailed overview of OncoVista Innovative Therapies's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

OncoVista Innovative Therapies (OncoVista Innovative Therapies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoVista Innovative Therapies Inc (OTCPK:OVIT) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

14785 Omicron Drive, Suite 104, San Antonio, TX, USA, 78245

Website

http://www.oncovista.com

OncoVista Innovative Therapies Inc is a biopharmaceutical company. It is engaged in developing anticancer therapies by utilizing tumor-associated biomarkers.

Executives

Alexander Ruckdaeschel	director	123 EAST 83RD STREET, APT 3-B, NEW YORK NY 10028
Paul A Mieyal	director	C/O WEXFORD CAPITAL LP, 411 WEST PUTNAM AVE, SUITE 125, GREENWICH CT 06830
Charles E Davidson	10 percent owner	C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602, WEST PALM BEACH FL 33401
Wexford Capital Lp	10 percent owner	777 WEST PUTNAM AVENUE, 1ST FLOOR, GREENWICH CT 06830
Joseph Jacobs	10 percent owner	C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602 EAST, WEST PALM BEACH FL 33401
Wexford Spectrum Trading Ltd	10 percent owner	411 WEST PUTNAM AVENUE, SUITE 125, GREENWICH CT 06830

OncoVista Innovative Therapies (OncoVista Innovative Therapies) Headlines

No Headlines